Back
RAD
Radiopharm Theranostics Limited
๐ฆ๐บ ASX
๐งฌ BIOTECHNOLOGY
๐ Overview
๐ Performance
๐ต Cost
๐ค Advanced
๐จโ๐ฉโ๐งโ๐ฆ Community
๐
-26.78%
Annual Growth
4 years average annual capital growth
๐ต
$ 500
Minimum Order
Due to regulatory requirements
๐
8
Pearlers Invested
Since January 2020
๐ Overview
Key information
๐ Fund Overview
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm has a pipeline of highly differentiated molecules spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including brain, lung, breast and pancreas. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
๐ Performance
Price History
-96.21%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
๐๏ธ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out โ๐ต Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out โโฑ๏ธ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out โ๐ต Costs
๐ผ
N/A
Management Fee
Included in unit price, not charged by Pearler
๐ธ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐ธ Net fee calculator๐ค Advanced information
Technical Info
๐ฐ Price*
$0.02
*Price may be up to 24 hours old
๐ฉโ๐ฉโ๐ฆ Community Insights
How our community is investing
๐ Pearlers invested in RAD
8
๐ Total Capital Earnings
$5K
๐ Average investment frequency
28 weeks
๐ต Average investment amount
$1,220
โฐ Last time a customer invested in RAD
28 days
RAD investor breakdown
๐ต Income of investors
More than 200k
150k - 200k
20%
100k - 150k
30%
50k - 100k
10%
Less than 50k
40%
๐ถ Age of investors
18 - 25
13%
26 - 34
25%
35 - 90
63%
๐ Legal gender of investors
Female
25%
Male
75%
Pearlers who invest in RAD also invest in...
Arafura Rare Earths Ltd. engages in the exploration and development of mineral resource properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-11-05. The firm produces rare earth products from the Nolans Project. The Nolans Project consists of a mine, process plant, including beneficiation, extraction and separation plants, and related infrastructure to be constructed and located at the Nolans site, approximately 135 kilometers north of Alice Springs in Australia's Northern Territory. Its rare earth products are Neodymium-Praseodymium (NdPr) oxide, and Mixed middle-heavy rare earths (SEG/HRE) oxide. NdPr oxide is the Company's flagship product, which is used by magnet and magnet alloy customers. The Companyโs primary products from the Nolans project are rare earths, which are used in catalytic converters in automobiles, consumer electronics, energy efficiency lighting, optics, alloys, advanced ceramics and permanent magnets that enable e-mobility and renewable energy applications.
๐ Performance (5Yr p.a)
46.07%
๐ Share price
$0.18 AUD
๐ HIGH PRICE GROWTH
โ๏ธ MINING
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
๐ Performance (5Yr p.a)
8.66%
๐ Share price
$106.01 AUD
๐ฆ๐บ AUSTRALIA
๐ธ FINANCIALS
๐งฑ MATERIALS
โณ๏ธ DIVERSIFIED
๐ HIGH PRICE GROWTH
Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the provision of business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The Companyโs lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).
๐ Performance (5Yr p.a)
145.79%
๐ Share price
$0.32 AUD
๐ฆ LOGISTICS
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
๐ Performance (5Yr p.a)
17.42%
๐ Share price
$141.95 AUD
๐ GLOBAL
๐ค TECHNOLOGY
โณ๏ธ DIVERSIFIED
๐ HIGH PRICE GROWTH
Polynovo Ltd. engages in the development of medical devices, utilizing the patented polymer technology NovoSorb. The company is headquartered in Melbourne, Victoria and currently employs 282 full-time employees. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.
๐ Performance (5Yr p.a)
-10.66%
๐ Share price
$1.20 AUD
๐ฉบ HEALTH CARE
Want more shares? Try these...